Daily Intelligence Brief
Ozempic NAION Docket Awakens With Six New Filings As Vision-Loss Claims Gain Traction
The Ozempic and Other GLP-1 RA Medications Products Liability Litigation (MDL 3163) (E.D. Pa., Judge Karen Marston) registered six new federal complaints in the past week — a notable acceleration for the nascent MDL focused on non-arteritic anterior ischemic optic neuropathy claims against Novo Nordisk and Eli Lilly. The filings include Turo v. Novo Nordisk Inc. (2:26-cv-02157) and Kenneth Merchant v. Eli Lilly and Company Inc. (2:26-cv-02176), both filed April 2, suggesting coordinated counsel are beginning to test the viability of vision-loss theories alongside the better-established gastroparesis allegations in the parallel Ozempic Gastroparesis Products Liability Litigation (MDL 3094). The NAION MDL remains significantly smaller than its gastroparesis counterpart, but the concentrated filing pattern indicates plaintiff firms are diversifying their GLP-1 litigation strategies beyond gastrointestinal injury. Judge Marston has not yet issued case management orders for the NAION docket, leaving discovery timelines and bellwether selection criteria unresolved as the plaintiff bar gauges defendant response.ByHeart Formula Botulism Cases Consolidated In New York Federal Court
Infant formula manufacturer ByHeart faces consolidated federal litigation in New York over botulism contamination allegations, with cases now centralized before a single judge following a transfer order. The consolidation covers claims that ByHeart's powdered formula caused infant botulism in multiple children, marking a rare food-safety MDL formation outside the traditional NEC formula context. The litigation emerges as FDA scrutiny of powdered infant formula manufacturing intensifies following the 2022 Abbott shutdown and subsequent supply chain disruptions. No case management schedule has been established, but the consolidation signals judicial recognition of common factual questions regarding manufacturing protocols and contamination testing. Plaintiff attorneys should monitor for potential coordination with the broader NEC Formula Products Liability Litigation (MDL 3026) (N.D. Ill.), though ByHeart's distinct manufacturing process may limit overlap.Hair Relaxer MDL Absorbs 38 New Filings As Colorado Moves Toward Mandatory Warning Labels
The Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation (N.D. Ill., MDL 3060) absorbed 38 new federal complaints between March 31 and April 2, with Keller Postman, Wallace Miller, and Peiffer Wolf among the active filers naming L’Oreal USA, Godrej SON Holdings, and Avlon Industries as defendants. Filings include Chesson v. Advanced Beauty, Inc. et al. (1:26-cv-03674) and Marshall v. L’Oreal USA, Inc. et al. (1:26-cv-03682), both filed April 2 in the Northern District of Illinois. The legislative backdrop sharpened this week as Colorado lawmakers advanced a bill requiring warning labels on hair products containing carcinogenic chemicals — the first state-level regulatory action targeting chemical hair relaxers since MDL formation. The combination of sustained filing velocity and emerging state regulation signals that plaintiff firms view the docket as a durable intake opportunity while legislative pressure may accelerate corporate settlement calculus ahead of Daubert proceedings.Generated by LexGenius Feed. Signals sourced from PACER federal court dockets, FDA/OpenFDA adverse event database, Federal Register, PubMed, and Google News.
